Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease

Table 1

Study design—administration of compounds.

Compound	Dose (mg/kg)	cIg/Vehicle	Mice per group^1	Dose/wk	Route
Rat anti-mouse TNF-α	25	rat IgG1	15^P/10^I,2	2	i.p.
Human TNFR-Fc (IgG1)	5–50	NaCl	10^P+I	3	i.p.
Rat anti-mouse IL-12p40	25	rat IgG2a	10^P+I	3	i.p.
Rat anti-mouse-IL-6	25	rat IgG1	10^p+I	3	i.p.
Human CTLA4-Ig (IgG1)	10	hIgG1-Fc^3	10^P+I	3	i.p.
Rat anti-mouse-α4β7	25	rat IgG2a	10^P+I	3	i.p.
Enro/metro^4	350/875	H2O	9^P/10^I	daily	p.o.
Cyclosporine	25	H2O	10^p	daily	p.o.

¹Five to ten unreconstituted mice were included in addition to the compound and the control group.
²P: prevention, I: intervention.
³ human IgG1-Fc.
⁴Treatment with enrofloxacin and metronidazole in the drinking water was initiated one week prior to transfer to let the mice adjust to the taste. Although we in pilot studies had identified a useful sugar mixture to mask the taste of metronidazole, the mice refused to drink and lost weight prior to adoptive transfer in the prevention study. Metronidazole was subsequently given orally by gavage once daily (this method was then also used for the intervention study).